Company intelligence / Profile preview
Dianosic
Strasbourg, Grand Est/Alsace region, Francedianosic.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Dianosic has demonstrated promising preclinical results for its ARIS-R program targeting chronic allergic rhinitis. The CAVI-T balloon device for epistaxis management has been CE-marked and launched commercially in Europe. Initial formulation studies have begun for CNS indications using the nose-to-brain approach.
- Therapeutic areas
- HematologyPulmonologyNeurology
- Modalities
- DeviceDrug-eluting polymer scaffoldPolymer-based drug delivery
- Industry
- Biotech
02
Drug pipeline
4 assets3 more assets in the full pipeline.
03
Partnerships
Collaborates with healthcare professionals and academic researchers; supported by regional innovation networks such as Quest for Health and Biovalley France. No major pharma partnerships disclosed.
Beyond the preview
Go deeper on Dianosic.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Dianosic.